Citations

Clear

1011 citation(s) found for "Barry, WT".

Diastolic and Systolic Heart Failure Are Distinct Phenotypes Within the Heart Failure Spectrum
Redfield, Margaret M. , Borlaug, Barry A.

Mayo Clinic

Circulation | May 9, 2011 | Volume: 123 | Issue: 18 | Pages: 2006-2014

10.1161/circulationaha.110.954388 | PMID 21555723 Get It

The Development of Primary Central Nervous System B-Cell Lymphoma in Multiple Sclerosis
Lyons, Mark , Boucher, Orland K., Birch, Barry D., Patel, Naresh P. , Patel, Naresh P

Mayo Clinic

The Neurohospitalist | March 23, 2011 | Volume: 1 | Issue: 3 | Pages: 133-136

10.1177/1941875211401751 | PMID 23983847 Get It

When coupled with classical clinical signs and symptoms, magnetic resonance imaging can significantly aid in the diagnosis of multiple sclerosis (MS). However, the differential diagnosis of multiple sclerosis is large and, in the absence of pathognomonic clinical features, can be challenging to diagnose initially. Some conditions, such as primary central nervous system lymphoma (PCNSL) and progressive multifocal leukoencephalopathy (PML), can mimic clinically some of the symptoms prominent in multiple sclerosis. Early treatment with corticosteroids can dramatically improve patient symptoms in MS and PCNSL. We report a case of a man diagnosed with histologically confirmed relapsing remitting multiple sclerosis who subsequently developed histologically confirmed primary central nervous system lymphoma. Immunosuppressant therapy in the treatment of multiple sclerosis may be a potential catalyst in the development of central nervous system lymphoma. The course of his disease and treatment are presented and the current literature reviewed.
Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010
Khachaturian, Zaven S., Petersen, Ronald C., Snyder, Peter J. , Khachaturian, Ara S. , Aisen, Paul , Leon, Mony J. de , Greenberg, Barry , Kukull, Walter A. , Maruff, Paul , Sperling, Reisa A., Stern, Yaakov , Touchon, Jacques, Vellas, Bruno , Andrieu, Sandrine , Weiner, Michael W. , Carrillo, Marı́a C., Bain, Lisa J. , Carrillo, María C. , Stern, Yaakov , Maruff, Paul

Mayo Clinic

Alzheimer's & Dementia | March 16, 2011 | Volume: 7 | Issue: 2 | Pages: 127-132

10.1016/j.jalz.2011.02.005 | PMID 21414553 Get It

The fourth Leon Thal Symposium (LTS2010) was convened in Toulouse, France, on November 3, 2010. This symposium reviewed design parameters that are necessary to develop comprehensive national databases on healthy aging. Such datasets offer the potential to serve as the foundation for a systems‐approach to solve the dual public health problems of: (1) early detection of people who are at elevated risk for Alzheimer's disease, and (2) the development of interventions to delay onset of, or prevent, late‐life dementia. The symposium considered three interrelated components of a National Database for Longitudinal Studies on Healthy Aging as follows: (a) a registry of healthy aging adults; (b) refined computer‐based assessments for data gathering, including assessments of behavioral/memory changes associated with aging that are appropriate for broad use in nonexpert settings; and (c) high performance computing/supercomputer‐based approaches for health data modeling and mining.
Left Ventricular Assist Device Therapy in Patients With Restrictive and Hypertrophic Cardiomyopathy
Topilsky, Yan , Pereira, Naveen L. , Shah, Dipesh K. , Boilson, Barry A. , Schirger, John A., Kushwaha, Sudhir S. , Joyce, Lyle D., Park, Soon J., Topilsky, Yan , Topilsky, Yan

Mayo Clinic

Circulation: Heart Failure | February 9, 2011 | Volume: 4 | Issue: 3 | Pages: 266-275

10.1161/circheartfailure.110.959288 | PMID 21303989 Get It

Background— Left ventricular assist device (LVAD) is being increasingly used in patients with end-stage dilated and ischemic cardiomyopathy. There have been no clinical trials addressing the use of LVAD therapy in patients with end-stage heart failure caused by restrictive (RCM) or hypertrophic cardiomyopathy (HCM). The purpose of this study was therefore to analyze the outcome of LVAD therapy in these patients. Methods and Results— Eighty-three patients received continuous axial flow LVAD (Heart mate II, Thoratec, Pleasanton, CA) from February 2007 to May 2010 at our institution. We analyzed the baseline characteristics and surgical and long-term impact of LVAD therapy in 8 patients with RCM or HCM and compared their outcomes with the 75 patients with dilated and ischemic cardiomyopathy. Compared with patients with ischemic or dilated cardiomyopathy, patients with RCM and HCM have significantly smaller left ventricular end-diastolic dimensions (52.5±6 mm versus 68.6±8 mm; P <0.0001) and increased thickness of septal (16 [12, 19] mm versus 10[8.5, 11] mm, P =0.0003) and higher left ventricular ejection fraction (21 [20, 36]% versus 17 [15, 22]%; P =0.0009). We found no difference in early mortality (12.5% versus 9.3%, P =0.57) or length of hospital stay (11 [8, 45] days versus 18.5 [12.2, 27.7] days; P =0.51) between the 2 groups. The right atrial pressure was higher (18 [15, 20] mm Hg versus 12 [9, 15] mm Hg, P =0.03), and pump flow was lower (4.3 [3.8, 4.5] L versus 5.2 [4.7, 5.5] L, P =0.001) after LVAD implantation in patients with RCM and HCM. Central venous catheter related infections were more common in patients with RCM and HCM (87.5% versus 44.5%, P =0.006). There was no difference in the total number of blood units transfused. Median (min, max) follow-up duration after LVAD implantation was 166 [1, 1044] days. The 1-year actuarial survival rate was not different between the 2 groups (87.5% [95% confidence interval, 52.9% to 97.8%] versus 73.2 [95% confidence interval, 60% to 85%]; P =0.77). Conclusions— Our preliminary data show that patients with end-stage heart failure caused by RCM or HCM may benefit from continuous axial flow LVAD therapy. This small study suggests that mortality is comparable with those patients who have dilated or ischemic cardiomyopathy, but right heart failure, prolonged inotropic use, and central venous catheter infections are more common in patients with RCM and HCM who were treated with LVAD. Because of the small numbers the differences should be interpreted cautiously, and prospective clinical trials would be required to recommend this therapy for these patients as bridge to transplantation or destination treatment.
Early Events in Retrovirus XMRV Infection of the Wild-Derived MouseMus pahari
Sakuma, Toshie, Tonne, Jason M., Squillace, Karen A., Ohmine, Seiga, Thatava, Tayaramma, Peng, Kah-Whye , Barry, Michael A. , Ikeda, Yasuhiro , Barry, Michael A

Mayo Clinic

Journal of Virology | November 18, 2010 | Volume: 85 | Issue: 3 | Pages: 1205-1213

10.1128/jvi.00886-10 | PMID 21084477 Get It

ABSTRACTA novel gammaretrovirus, xenotropic murine leukemia virus-related virus (XMRV), has been identified in patients with prostate cancer and in patients with chronic fatigue syndromes. StandardMus musculuslaboratory mice lack a functional XPR1 receptor for XMRV and are therefore not a suitable model for the virus. In contrast, Gairdner's shrew-mice (Mus pahari) do express functional XPR1. To determine whetherMus paharicould serve as a model for XMRV, primaryMus paharifibroblasts and mice were infected with cell-free XMRV. Infection of cellsin vitroresulted in XMRV Gag expression and the production of XMRV virions. After intraperitoneal injection of XMRV intoMus paharimice, XMRV proviral DNA could be detected in spleen, blood, and brain. Intravenous administration of a green fluorescent protein (GFP) vector pseudotyped with XMRV produced GFP+CD4+T cells and CD19+B cells. Mice mounted adaptive immune responses against XMRV, as evidenced by the production of neutralizing and Env- and Gag-specific antibodies. Prominent G-to-A hypermutations were also found in viral genomes isolated from the spleen, suggesting intracellular restriction of XMRV infection by APOBEC3in vivo. These data demonstrate infection ofMus pahariby XMRV, potential cell tropism of the virus, and immunological and intracellular restriction of virus infectionin vivo. These data support the use ofMus paharias a model for XMRV pathogenesis and as a platform for vaccine and drug development against this potential human pathogen.
Adeno-Associated Virus Serotype 8 Gene Transfer Rescues a Neonatal Lethal Murine Model of Propionic Acidemia
Chandler, Randy J. , Chandrasekaran, Suma, Carrillo, Nuria , Senac, Julien S., Hofherr, Sean, Barry, Michael A. , Venditti, Charles P. , Barry, Michael A

Mayo Clinic

Human Gene Therapy | October 15, 2010 | Volume: 22 | Issue: 4 | Pages: 477-481

10.1089/hum.2010.164 | PMID 20950151 Get It

Long-term follow-up of deep brain stimulation for Meige syndrome
Lyons, Mark , Birch, Barry D., Hillman, Renee, Boucher, Orland K., Evidente, Virgilio Gerald H.

Mayo Clinic

Neurosurgical Focus | July 30, 2010 | Volume: 29 | Issue: 2 | Pages: E5

10.3171/2010.4.focus1067 | PMID 20672922 Get It

Object Meige syndrome is characterized by blepharospasm, cervical dystonia, and facial oromandibular dystonia. The medical treatment of this condition is largely unsuccessful over time and is a major source of decreased quality of life in those patients suffering from this disease. Recent advances in the application of deep brain stimulation (DBS) surgery techniques for many disorders have prompted several recent reports of DBS for medically refractory cases of Meige syndrome. While the etiology for this disorder is unknown, it is considered by many investigators to be a form of idiopathic torsion dystonia. Pallidal stimulation is widely considered to be effective for dystonia. Methods The authors report the long-term results of bilateral globus pallidus internus (GPi) or subthalamic nucleus (STN) stimulation in 3 patients with Meige syndrome and 1 patient with Parkinson disease and associated craniofacial dystonia treated at their center. Results Initial 12-month and long-term follow-up Burke-Fahn-Marsden scores were substantially improved in all 4 patients compared with preoperative scores. Conclusions Bilateral GPi DBS may be an effective and safe treatment for medically refractory Meige syndrome. The results are comparable with those reported in the literature. Sustained and long-term improvement in symptoms does appear to be reproducible across reports. The authors' patient with Parkinson disease and associated craniofacial dystonia syndrome undergoing bilateral STN DBS noted immediate and sustained improvement in his symptoms. Further study is required, but these results, along with the other reports, suggest that bilateral GPi DBS is an effective treatment for medically refractory Meige syndrome.
Regulation of Circulating Progenitor Cells in Left Ventricular Dysfunction
Boilson, Barry A. , Larsen, Katarína, Harbuzariu, Adriana , Delacroix, Sinny , Kořínek, Josef , Froehlich, Harald , Bailey, Kent R. , Scott, Christopher G. , Shapiro, Brian P. , Boerrigter, Guido, Chen, Horng H. , Redfield, Margaret M. , Burnett, John C. , Simari, Robert D., Scott, Christopher

Mayo Clinic

Circulation: Heart Failure | June 24, 2010 | Volume: 3 | Issue: 5 | Pages: 635-642

10.1161/circheartfailure.109.879437 | PMID 20573992 Get It

Background— Reductions in numbers of circulating progenitor cells (CD34+ cell subsets) have been demonstrated in patients at risk for, or in the presence of, cardiovascular disease. The mediators of these reductions remain undefined. To determine whether neurohumoral factors might regulate circulating CD34+ cell subsets in vivo, we studied complementary canine models of left ventricular (LV) dysfunction. Methods and Results— A pacing model of severe LV dysfunction and a hypertensive renal wrap model in which dogs were randomized to receive deoxycorticosterone acetate (DOCA) were studied. Circulating CD34+ cell subsets including hematopoietic precursor cells (HPCs: CD34+/CD45 dim /VEGFR2−) and endothelial progenitor cells (EPCs: CD34+/CD45−/VEGFR2+) were quantified. Additionally, the effect of mineralocorticoid excess on circulating progenitor cells in normal dogs was studied. The majority of circulating CD34+ cells expressed CD45dimly and did not express VEGFR2, consistent with an HPC phenotype. HPCs were decreased in response to pacing, and this decrease correlated with plasma aldosterone levels (Spearman rank correlation=−0.67, P =0.03). In the hypertensive renal wrap model, administration of DOCA resulted in decreased HPCs. No changes were seen in EPCs in either model. Normal dogs treated with DOCA exhibited a decrease in HPCs in peripheral blood but not bone marrow associated with decreased telomerase activity. Conclusions— This is the first study to demonstrate that mineralocorticoid excess, either endogenous or exogenous, results in reduction in HPCs. These data suggest that mineralocorticoids may induce accelerated senescence of progenitor cells, leading to their reduced survival and decline in numbers.
Don't Patients Have Two Knees?
Harrison, Barry, DeStephano, Christopher C. , Ruyter, Martin L. De

Mayo Clinic

Anesthesiology | June 18, 2010 | Volume: 113 | Issue: 1 | Pages: 256-257

10.1097/aln.0b013e3181e19d4e | PMID 20574231 Get It

Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction
Sorajja, Paul , Redfield, Margaret M. , Borlaug, Barry A. , Nishimura, Rick A. , Sorajja, Paul , Lam, Carolyn S.P.

Mayo Clinic

Circulation: Heart Failure | June 11, 2010 | Volume: 3 | Issue: 5 | Pages: 588-595

10.1161/circheartfailure.109.930701 | PMID 20543134 Get It

Background— When advanced, heart failure with preserved ejection fraction (HFpEF) is readily apparent. However, diagnosis of earlier disease may be challenging because exertional dyspnea is not specific for heart failure, and biomarkers and hemodynamic indicators of volume overload may be absent at rest. Methods and Results— Patients with exertional dyspnea and ejection fraction >50% were referred for hemodynamic catheterization. Those with no significant coronary disease, normal brain natriuretic peptide assay, and normal resting hemodynamics (mean pulmonary artery pressure <25 mm Hg and pulmonary capillary wedge pressure [PCWP] <15 mm Hg) (n=55) underwent exercise study. The exercise PCWP was used to classify patients as having HFpEF (PCWP ≥25 mm Hg) (n=32) or noncardiac dyspnea (PCWP <25 mm Hg) (n=23). At rest, patients with HFpEF had higher resting pulmonary artery pressure and PCWP, although all values fell within normal limits. Exercise-induced elevation in PCWP in HFpEF was confirmed by greater increases in left ventricular end-diastolic pressure and was associated with blunted increases in heart rate, systemic vasodilation, and cardiac output. Exercise-induced pulmonary hypertension was present in 88% of patients with HFpEF and was related principally to elevated PCWP, as pulmonary vascular resistances dropped similarly in both groups. Exercise PCWP and pulmonary artery systolic pressure were highly correlated. An exercise pulmonary artery systolic pressure ≥45 mm Hg identified HFpEF with 96% sensitivity and 95% specificity. Conclusions— Euvolemic patients with exertional dyspnea, normal brain natriuretic peptide, and normal cardiac filling pressures at rest may have markedly abnormal hemodynamic responses during exercise, suggesting that chronic symptoms are related to heart failure. Earlier and more accurate diagnosis using exercise hemodynamics may allow better targeting of interventions to treat and prevent HFpEF progression.